KRAS and Miyoshi myopathy: With 25.7% percent of our study cohort affected by known pathogenic KRAS mutations (G13D, Q61H, and G12A/R/V), our findings underline the possible therapeutic utilities of targeted KRAS inhibitors in patients with MM.